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Abstract
Introduction
The EXIST-2 (NCT00790400) study demonstrated the superiority of everolimus over pla-
cebo for the treatment of renal angiomyolipomas associated with tuberous sclerosis com-
plex (TSC) or sporadic lymphangioleiomyomatosis (LAM). This post hoc analysis of EXIST-
2 study aimed to assess angiomyolipoma tumor behavior among patients who submitted to
continued radiographic examination following discontinuation of everolimus in the noninter-
ventional follow-up phase.
Methods
For patients who discontinued everolimus at the completion of extension phase for reasons
other than angiomyolipoma progression, a single CT/MRI scan of the kidney was collected
after 1 year of treatment discontinuation. Changes from baseline and from the time of evero-
limus discontinuation in the sum of volumes of target angiomyolipoma lesions were
assessed in the non-interventional follow-up phase (data cutoff date, November 6, 2015).
Results
Of the 112 patients who received1 dose of everolimus and discontinued treatment by the
end of extension phase, 34 (30.4%) were eligible for participation in the non-interventional
follow-up phase. Sixteen of 34 patients were evaluable for angiomyolipoma tumor behavior
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as they had at least one valid efficacy assessment (i.e. kidney CT/MRI scan) after everoli-
mus discontinuation. During the non-interventional follow-up phase, compared with base-
line, two patients (12.5%) experienced angiomyolipoma progression (angiomyolipoma-
related bleeding [n = 1], increased kidney volume [n = 1]). Five patients out of 16 (31.3%)
experienced angiomyolipoma progression when compared with the angiomyolipoma tumor
assessment at everolimus discontinuation. The median (range) percentage change in
angiomyolipoma tumor volume (cm3) from baseline was −70.56 (−88.30; −49.64) at time of
everolimus discontinuation (n = 11), and −50.55 (−79.40; −23.16) at week 48 (n = 7) after
discontinuation of everolimus. One patient death was reported due to angiomyolipoma
hemorrhage.
Conclusions
Angiomyolipoma lesions displayed an increase in volume following discontinuation of evero-
limus in patients with renal angiomyolipoma or sporadic LAM associated with TSC, but there
was no evidence of rapid regrowth.
Trial registration
ClinicalTrials.gov NCT00790400
Introduction
Angiomyolipomata are the most common renal manifestations in patients with tuberous scle-
rosis complex (TSC) developing during later childhood and adolescence.[1, 2] Renal angio-
myolipomata are benign tumors composed of blood vessels, smooth muscle, and adipose
tissue.[3] They belong to a family of neoplasms called perivascular epithelioid cell tumors
(PEComas) which include pulmonary lymphangioleiomyomatosis (LAM).[3] LAM is a pro-
gressive lung disease characterized by infiltration of smooth muscle cells and formation of
parenchymal cysts. The cells comprising the LAM lesions and angiomyolipomata appear to
arise from a common source.[3, 4] Approximately, 80% of patients with TSC develop renal
angiomyolipomata and mostly because of a definitive mutation of the TSC1 or TSC2 gene.[4]
Renal angiomyolipomata may occur unilaterally or bilaterally and historically were the most
common cause of premature mortality in adults with TSC.[5] Angiomyolipomata are mostly
asymptomatic and slow growing. Studies that have explored the growth rates of angiomyolipo-
mata showed mean growth rates within a range of0.25 cm/year, 0.37 cm/year, and 0.5 cm/
year.[6–8] Angiomyolipomata display linear growth and tend to be significantly more symp-
tomatic as they grow.[6, 9] Large angiomyolipomata measuring >3 to 4 cm in diameter may
develop a vascular aneurysm and life-threatening hemorrhage or compress normal renal tis-
sue, potentially leading to renal failure.[5, 10] Treatment with mammalian target of rapamycin
(mTOR) inhibitors is recommended for asymptomatic, growing angiomyolipomata measur-
ing larger than 3 cm in diameter.[11] In the phase 3 EXIST-2 trial, the mTOR inhibitor everoli-
mus reduced renal angiomyolipoma volume by50% from baseline to the end of the core
phase in 42% of patients after a median treatment duration of 38 weeks. Long-term results
from this study demonstrated sustained tumor regression with everolimus. The proportion of
patients with a50% reduction in renal angiomyolipoma increased over time to 54% at ~2.5
years, and 58% at ~4 years.[12, 13] Although angiomyolipoma lesions shrink and stabilize with
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mTOR inhibitor treatment, there is a tendency to increase volume after the therapy is discon-
tinued.[4, 14] Limited evidence is currently available to understand the rebound growth fol-
lowing discontinuation.[14] The aim of this post hoc analysis of the EXIST-2 study was to
better characterize tumor response status for up to 1-year after discontinuation of everolimus
treatment in patients with renal angiomyolipoma associated with TSC or sporadic LAM who
submitted to continued radiographic assessment in the non-interventional follow-up phase.
Methods
EXIST-2 (NCT00790400) was a prospective, phase 3, multicenter, randomized, double-blind
trial with a core phase followed by an extension phase and a non-interventional follow-up
phase. A complete description of the study participants, design, and outcomes has been pub-
lished.[13, 15] In brief, eligible patients were18 years of age with at least one renal angio-
myolipoma measuring3 cm in its longest diameter, as measured by computed tomography
(CT) or magnetic resonance imaging (MRI), and had a definitive diagnosis of TSC according
to the TSC consensus criteria or sporadic LAM as confirmed by biopsy or chest CT scan.
Patients were excluded if they had angiomyolipoma-related bleeding or embolization during
the 6 months prior to randomization or if their angiomyolipoma required surgery at the time
of randomization or had impaired lung function. The primary analysis of the data from core
phase (data cutoff June 30, 2011) favored everolimus over placebo in reducing angiomyoli-
poma volume. The study was then unblinded on September 9, 2011 and all patients (including
those who had received placebo during the core phase) received everolimus in the open-label
extension phase, until 4 years after the last patient was randomized (last patient, last treatment,
January 28, 2015). Everolimus was initiated at oral dose of 10 mg/day and dose adjusted based
on tolerability. Patients were treated with everolimus until angiomyolipoma progression, intol-
erable toxicity or any other reason for discontinuation. The definition of angiomyolipoma pro-
gression is described in detail previously.[13, 15]
All patients who had either completed the extension phase or who discontinued everolimus
for reasons other than angiomyolipoma progression or due to adverse events (AEs) were
allowed to participate in the non-interventional follow-up phase. Patients were excluded to
participate in the non-interventional follow-up phase if they started treatment with systemic
mTOR inhibitors, or had embolization or angiomyolipoma requiring partial/complete
nephrectomy immediately after everolimus discontinuation. A single kidney CT/MRI scan
was to be performed approximately one year after the discontinuation of treatment with evero-
limus in the non-interventional follow-up phase. If a patient needed any intervention follow-
ing treatment discontinuation, a kidney CT/MRI was to be performed prior to the start of
intervention, and then the non-interventional follow-up phase ended. Interventions included
commercial everolimus, off label rapamycin, embolization, or nephrectomy. Data collected
during the non-interventional follow-up phase included angiomyolipoma-related bleeding
events, AEs (only spontaneously reported by the patient were captured), use of concomitant
medications and non-drug therapies for the treatment of angiomyolipoma or angiomyoli-
poma-related disease progression. End-of study assessment was planned after all patients have
either completed the one-year non-interventional follow-up phase or have exited the study. In
addition to the initial definition based on baseline volume, a sensitivity analysis was performed
using a different definition for angiomyolipoma progression during the non-interventional
follow-up phase: angiomyolipoma volume increased by25% from end of treatment or20%
increase in the volume of either kidney from end of treatment, appearance of new angiomyoli-
poma1 cm, an increase in the longest diameter of angiomyolipoma lesion that was <1 cm at
the end of treatment to1 cm during the non-interventional follow-up phase, or grade2
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angiomyolipoma-related bleeding according to the NCI-CTCAE, version 3.0.[16] Angiomyoli-
poma progression was presented as a percentage rate along with an exact 95% confidence
interval (CI) obtained using the Clopper-Pearson method. Baseline data was summarized by
descriptive statistics. The assessment of efficacy and safety was restricted to patients without
angiomyolipoma progression or anti-TSC therapy (non-study systemic anti-angiomyolipoma
therapies or angiomyolipoma-related surgeries) at the time of everolimus discontinuation.
Patients with at least one valid efficacy assessment during the non-interventional follow-up
period were evaluable for efficacy analysis. Statistical analysis was performed using SAS soft-
ware (SAS Institute Inc., Cary, NC, USA). Here we present the angiomyolipoma tumor
response status among patients who submitted to continued radiographic assessment follow-
ing discontinuation of everolimus in the non-interventional follow-up phase at the data cut-
off date of November 6, 2015.
All patients and or legal representatives provided written informed consent according to
local guidelines before enrolment and before participating in the non-interventional follow-up
phase. Independent ethics committees and/or local review boards approved the protocol (S1
and S2 Appendices), which was executed according to the International Conference on
Harmonization Good Clinical Practice guidelines.
Results
A total of 118 patients with renal angiomyolipoma associated with TSC or sporadic LAM were
enrolled from 24 centers in 11 countries between April 28, 2009 and December 30, 2010. Over-
all, 112 patients received at least one dose of everolimus during the core phase and/or the
extension phase, and had discontinued treatment with everolimus by the end of extension
phase. Only 34 patients out of 112 (30.4%) were eligible for assessments in the noninterven-
tional follow-up phase (Fig 1).
The remaining 78 patients (69.6%) were not eligible either because they received commer-
cial everolimus (or another anti-TSC therapy) after everolimus discontinuation (64.3%) or had
an angiomyolipoma progression at the time of everolimus discontinuation (13.4%). The most
common reason for everolimus discontinuation among the 34 patients was AEs, reported in
nine patients (26.5%). Thirteen patients completed the extension phase as per the study proto-
col, six withdrew consent, one withdrew due to protocol deviation, two withdrew due to
administrative problems, one withdrew due to loss to follow-up, and one withdrew due to
abnormal laboratory value. One patient (originally randomized to everolimus) with a history
of intractable seizures died; this fatal case was reported with the initial study report.[13] Only
16 patients of the 34 were evaluable for efficacy as they had at least one valid efficacy assess-
ment (i.e. kidney CT/MRI scan) after everolimus discontinuation. Eleven patients were ran-
domized to everolimus starting in the core phase while the remaining five patients were
randomized to placebo and switched to everolimus starting in the extension phase. The rea-
sons for treatment discontinuation for the 16 patients were treatment completion as per proto-
col (56.3%), AEs (37.5%), and administrative problems (6.3%).
The median age of the 16 patients evaluable for efficacy in the non-interventional follow-up
phase was 34.9 years (range, 20.5–49.4) at baseline and 38.2 years (range, 25.1–52.1) at end of
treatment, and 50% were female (Table 1). The median sum of volumes of target lesions at
baseline was 154.67 cm3 (range, 24.1–861.4). The median duration of study follow-up since
discontinuation of everolimus was 11.1 months (range, 3.2–39.1). The median duration of
everolimus exposure was 43.7 months (range, 0.46–60.5), and the median dose intensity was
9.89 mg/day (range, 3.9–10).
Angiomyolipoma tumor behavior after discontinuation of everolimus therapy
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Fig 1. CONSORT flow diagram of patient disposition in the double-blind core phase followed by open-label extension phase and noninterventional follow-up
phase. aPatients with angiomyolipoma progression were unblinded at the end of the double-blind phase, and patients who were on placebo were allowed to cross over to
open-label everolimus. bPatients were evaluable for noninterventional follow-up phase as they had at least one adequate efficacy assessment (CT/MRI scan).
https://doi.org/10.1371/journal.pone.0201005.g001
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Efficacy outcomes
Angiomyolipoma tumor progression at the time of primary analysis was observed in 3 patients
treated with everolimus (3/79, 3.8%) and 8 patients treated with placebo (8/39, 20.5%).[13] At
the end of the extension phase, 16 patients reported angiomyolipoma progression (16/112,
14.3%).[17] At the end of the non-interventional follow-up phase, angiomyolipoma progres-
sion was observed in 2/16 patients (12.5%) when compared to the baseline. Among the 2
patients, one patient was already considered to have angiomyolipoma progression at the end
of the extension phase. Primary reasons for progression in 2 patients were angiomyolipoma-
related bleeding of grade2 in one patient (6.3%) and increase in kidney volume only in
another patient (6.3%). Further detailed evaluation of the CT scans by the investigator for the
patient with increased kidney volume revealed an increase in cyst volume which may have
contributed to the overall kidney volume increase as the kidney volume measurements also
included cyst volume. However, cyst volume was not centrally collected and assessed sepa-
rately. Five patients (31.3%) reported angiomyolipoma progression at the end of the non-inter-
ventional follow-up phase when compared with the end of treatment, as per the sensitivity
analysis. The most common reasons for progression in these 5 patients included increase in
both tumor and kidney volume in three patients (18.8%), angiomyolipoma-related bleeding of
grade2 in one patient (6.3%), and increase in tumor volume only in one patient (6.3%).
The median percentage change in the sum of volumes of target angiomyolipoma lesions
(cm3) from baseline (119.31; range, 24.06–861.36) to end of treatment (27.49; range, 4.03–
253.61) was −70.56% (range, −88.30 to −49.64; n = 11 evaluable patients), and from baseline
(146.79; range, 24.06–861.36) to week 48 of non-interventional follow-up phase (87.32; range,
4.96–312.68) was −50.55% (range, −79.40 to −23.16; n = 7 evaluable patients; Table 2). The
median percentage change in the sum of volumes of target angiomyolipoma lesions (cm3)
from end of treatment (46.63; range, 4.03–253.61) to week 48 of the non-interventional follow-
Table 1. Patient demographics and disease characteristics.
Characteristic Evaluable patientsa (N = 16)
Median age at baseline, years (range) 34.9 (20.5–49.4)
Median age at time of treatment discontinuation, years (range) 38.2 (25.1–52.1)
Sex, n (%)
Male 8 (50.0)
Female 8 (50.0)
Race, n (%)
Caucasian 14 (87.5)
Asian 2 (12.5)
WHO performance status at baseline, n (%)
0 11 (68.8)
1 4 (25.0)
2 1 (6.3)
Median body mass index at baseline, kg/m2 (range) 24.25 (19.8–29.0)
Median body surface area at baseline, m2 (range) 1.83 (1.62–2.14)
Sum of volumes of target renal angiomyolipoma lesions, cm3
Mean (standard deviation) 248.72 (254.9)
Median (range) 154.67 (24.1–861.4)
aPatients with at least one valid efficacy assessment during the non-interventional follow-up phase.
https://doi.org/10.1371/journal.pone.0201005.t001
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up phase (87.32; range, 4.96–312.68) was 52.53% (range, −23.16 to 87.25; n = 7 evaluable
patients; Table 2).
Safety outcomes
Safety results during treatment with everolimus were reported in detail in prior publications.
[12, 13, 15] No renal hemorrhages were observed during the cumulative 390.8 patient-years of
everolimus treatment.[17] During the non-interventional follow-up phase, one patient died
after 5.8 months of treatment discontinuation due to angiomyolipoma hemorrhage. The
patient was exposed to everolimus treatment for approximately 4.1 years. Five patients
reported AEs after 28-days of treatment discontinuation which included post-procedural com-
plications, procedural pain and arthralgia for the same patient, hypersensitivity, decrease in
weight, anemia and hemorrhage reported in one patient each.
Discussion
This post hoc analysis of EXIST-2 demonstrated tumor growth after discontinuation of evero-
limus in patients with renal angiomyolipoma associated with TSC or sporadic LAM. However,
there was no evidence of rapid regrowth as the increase in angiomyolipoma lesion volume fol-
lowing treatment discontinuation did not exceed the lesion volume at baseline, even among
patients who displayed progression. The angiomyolipoma progression rates were comparable
between patients of the non-interventional follow-up phase (31.3%) and the patients treated
with placebo during the double-blind core phase (20.5%).[13] To the best of our knowledge,
this is the first ever study of everolimus reporting the tumor behavior after treatment discon-
tinuation. Previously, an increase in angiomyolipoma volume was reported with discontinua-
tion from sirolimus therapy, but did not return completely to the baseline values. The reason
for angiomyolipoma progression could be due to impaired apoptosis or increase in angiomyo-
lipoma size or volume.[4] In EXIST-2, 12 of the 16 evaluable patients experienced an increase
in angiomyolipoma volume compared to their most recent tumor volume assessed before
treatment discontinuation (EOT). A median angiomyolipoma growth of 52.53% was observed
at 48 weeks after everolimus discontinuation.
Long-term safety analysis of EXIST-2 had shown that everolimus was well-tolerated and the
AEs remained consistent with the previous reports.[13, 15] Angiomyolipoma-related bleeding
event was reported only in one patient during the non-interventional follow-up phase, and
during an overall 390.8 patient-years of treatment with everolimus, no bleeding events were
Table 2. Median sum of volumes of target angiomyolipoma lesions at baseline, EOT, and week 48 of non-inter-
ventional follow-up phase, and percentage change from baseline to EOT/week 48 of non-interventional follow-up
phase and from EOT to week 48 of non-interventional follow-up phase.
Median (range) Evaluable patients at
EOT (N = 11)
Evaluable patients at week 48 of non-
interventional follow-up phase (N = 7)
Sum of volumes at baseline, cm3 119.31 (24.06–861.36) 146.79 (24.06–861.36)
Sum of volumes at EOT, cm3 27.49 (4.03–253.61) 46.63 (4.03–253.61)
Sum of volumes at week 48 of non-
interventional follow-up phase, cm3
NA 87.32 (4.96–312.68)
Percentage change from baseline, % −70.56 (−88.30 to
−49.64)
−50.55 (−79.40–23.16)
Percentage change from EOT, % NA 52.53 (−23.16–87.25)
Abbreviations: EOT = end of treatment; NA = not applicable.
https://doi.org/10.1371/journal.pone.0201005.t002
Angiomyolipoma tumor behavior after discontinuation of everolimus therapy
PLOS ONE | https://doi.org/10.1371/journal.pone.0201005 September 7, 2018 7 / 10
reported.[17] Six patients reported angiomyolipoma-related bleeding events in the year before
randomization. These observations suggest a considerably lower annual rate of angiomyoli-
poma-related bleeding for patients receiving everolimus when compared with patients not
receiving everolimus either before or after the treatment portion of the study. Previous studies
suggested a correlation between angiomyolipoma size and risk of hemorrhage.[18] The aneu-
rysm and tumor sizes are considered as the main predictors of renal hemorrhage.[18] Angio-
myolipomata tend to become symptomatic as they grow. Previous studies showed tumor
growth in 27% to 53% of lesions measuring <4 cm and in 46% to 75% of lesions measuring >4
cm over a follow-up period of up to 4 years.[7, 8] This suggests that treatment that maintains
or reduces angiomyolipoma lesions may reduce the risk of bleeding.
Fewer evaluable patients to assess tumor response after treatment discontinuation is a limi-
tation of this analysis as more robust predictions of tumor behavior after cessation of everoli-
mus treatment are difficult. In summary, angiomyolipoma lesion volume increased for up to
one year after discontinuation of everolimus in patients with renal angiomyolipoma associated
with TSC or sporadic LAM, compared to their most recent tumor volume assessment per-
formed prior to treatment discontinuation; though the angiomyolipoma volume did not
exceed that measured at baseline. The results of our study show that persistence of clinically
significant angiomyolipoma volume reduction may require ongoing treatment with everoli-
mus in patients with TSC.
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